Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213070 | 0.91 | MEN1 (0.43) | TLR7TLR8 | |
| SCHEMBL211223 | 0.87 | TLR7 (0.51) | TLR7TLR8 | |
| SCHEMBL212714 | 0.87 | TLR7 (0.51) | TLR7TLR8 | |
| SCHEMBL20766732 | 0.82 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL20448080 | 0.81 | TLR7 (0.51) | TLR7TLR8 | |
| SCHEMBL212885 | 0.81 | TLR7 (0.53) | TLR7ALDH1A1SMN1; SMN2 | |
| SCHEMBL213038 | 0.79 | TLR7 (0.49) | TLR7 | |
| SCHEMBL212611 | 0.78 | TLR7 (0.51) | TLR7TLR8ALDH1A1SMN1; SMN2 | |
| SCHEMBL26981129 | 0.75 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL30031494 | 0.75 | TLR7 (0.57) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005082914-A2 | MODULATORS OF LYSOPHOSPHATIDIC ACID (LPA) SIGNALING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-09-09 | — | — | WO | claimed |
| EP-1948173-A2 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | Coley Pharmaceutical Group, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080071116-A1 | Modulators of Lysophosphatidic Acid (Lpa) Signaling and the Use Thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2007056112-A2 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2005082914-A2 | MODULATORS OF LYSOPHOSPHATIDIC ACID (LPA) SIGNALING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080071116-A1 | Modulators of Lysophosphatidic Acid (Lpa) Signaling and the Use Thereof | LPAR4, LPAR2, LPAR6 | TLR7 1221/4885TLR8 1726/4885ALDH1A1 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.